teaser
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
Adding capecitabine to gemcitabine in patients with advanced pancreatic cancer and a good Karnofsky performance score (KPS) prolongs survival, research has found.
The phase III trial, published in the Journal of Clinical Oncology, investigated the efficacy and safety of gemcitabine alone or in combination with capecitabine. It involved 319 advanced/metastatic pancreatic cancer patients randomised to receive either (a) oral capecitabine 650mg/m2 twice daily on days 1
